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Background: Type 1 diabetes mellitus is associated with a high risk for early atherosclerotic complications. Altered
lipids and lipoprotein metabolism in chronic diabetes mellitus is associated with pathogenesis of atherosclerosis
and other cardiovascular diseases. The aim of this study was to investigate the effects of 4 weeks resistance training
on plasma lipid profile, fatty acid binding protein (FABP) 4 and apolipoprotein (apo) A-I levels in type 1 diabetic rats.
Methods: Thirty two male Wister rats (12–14 weeks old) were randomly divided into four groups: non-diabetic
control; non-diabetic trained; diabetic control; diabetic trained. The rats in training groups were subjected to a
resistance training program (3 days/wk, for 4 wk) consisted of climbing a ladder carrying a load suspended from
the tail.
Results: Diabetic inducing increased plasma apoA-I and decreased FABP4 levels compared with non-diabetic
control group (respectively, P = 0.001 & P = 0.041). After 4 weeks’ resistance training, plasma levels of apoA-I and
FABP4 in the diabetic trained rats were significantly higher compared with the diabetic control group (respectively,
P = 0.003 & P = 0.017). Plasma HDL-C level in diabetic trained group was higher than diabetic control group
(P = 0.048). Liver triglycerides concentrations were significantly lower in both trained (non-diabetic and diabetic)
groups compared with their control groups (respectively, P = 0.041 and P = 0.002).
Conclusion: These data indicated that resistance training may be an efficient intervention strategy to increase
plasma apoA-I, HDL-C and FABP4 concentrations, along with decreases liver triglycerides in streptozotocin induced
diabetic rats. Further research is needed to elucidate physiological significance of circulating FABP4 levels.
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The incidence of diabetes mellitus is increasing worldwide,
and data from recent studies suggest that the increase is
exponential rather than linear [1]. This metabolic disease
is associated with hyperglycemia, which leads to many
pathological changes, including peripheral neuropathy, ne-
phropathy, retinopathy, microvascular lesions, liver disease
and a variety of diseases that diminish the quality of life
and life expectancy of the patients [2,3]. Type 1 diabetes
mellitus is associated with a high risk for early atheroscler-
otic complications. In this patients risk of coronary heart
disease is 4 to 8 more excessive than general population* Correspondence: Safarzadeh77@gmail.com
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icle, unless otherwise stated.[4]. Lipids play an important role in maintaining the integ-
rity of biomembrane structure and functions. Altered
lipids and lipoprotein metabolism in chronic diabetes mel-
litus is associated with pathogenesis of atherosclerosis and
other cardiovascular diseases [5]. Abnormalities in plasma
lipids and lipoprotein patterns due to defect in insulin in-
sufficiency has been well documented in both type I and
type II diabetes mellitus [6]. In these patients, classic lipid
profile may be normal but patient is at increased risk of
atherosclerosis. Measurement of apolipoproteins in dia-
betic patients may be helpful in diabetic patients at risk of
cardiovascular diseases [7]. Apolipoprotein A-I (apoA-I) is
the major protein of high-density lipoprotein (HDL) parti-
cles and thus provides an indication of the number ofBioMed Central Ltd. This is an Open Access article distributed under the terms
(http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this art-
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one relationship in this case [8].
Fatty acid binding protein (FABP) 4 (or adipocyte FABP
or adipocyte protein 2 [aP2]) serves as a carrier protein for
fatty acids and other lipophilic substances between extra-
and intracellular membranes, and has been introduced as
a novel adipokine that is secreted from mature adipocytes
into bloodstream [9]. Although the function of serum
FABP4 has not yet been elucidated, results from recent
publications suggest a systemic effect of FABP4 on periph-
eral tissues [10]. Previous studies indicated that circulating
FABP4 levels was increased in overweight and obese sub-
jects compared with lean controls and was associated with
markers of insulin resistance and obesity [11-13]. Further-
more, it was demonstrated that serum FABP4 levels are
increased in patients with gestational diabetes mellitus,
preeclampsia, and renal dysfunction [14-16]. Paradoxic-
ally, lower circulating levels of FABP4 found in chronic
pancreatitis patients [17], and lean compared with obese
type 1 diabetic patients [18].
In addition to dietary control, physical exercise has been
heavily used as a non-pharmaceutical treatment for the
control and reduction in abnormal levels of circulating
lipids and glucose in individuals with metabolic dysfunc-
tions such as diabetes [19]. Although the effect of chronic
aerobic exercise upon lipid profile has been demonstrated,
few studies have investigated this effect under resistance
exercise conditions in subjects with type 1 diabetes.
Among the exercise interventions, resistance training has
been shown to be efficient in decreasing the adipose tissue
depots in rats [20-22]. Resistance training also improves
body composition, physical fitness, quality of life, and lipid
profile [23,24].
Considering the well-established capacity of resistance
training for increasing both muscle mass and strength, as
well as improving the lipid profile, adiposity and obesity-
associated inflammation, we have sought to investigate the
effects of a resistance training program, mainly composed
of concentric contractile force production on plasma
FABP4, apoA-I and lipids profile in plasma and liver tissue
in Streptozotocin-induced diabetic rats.
Materials and methods
Animals
Thirty two male Wister rats (289 ± 23 g, 12–14 weeks old)
were utilized at the beginning of this study. Animals were
housed in cages under controlled light/dark (12/12 h) and
temperature (22 ± 2°C) conditions, and were provided with
standard food and water ad libitum. The animals were ac-
climated to their living conditions for 1 week. Then they
were randomly separated into one of four experimental
groups (N = 8 in each group): non-diabetic control (non-
DC); non-diabetic trained (non-DT); diabetic control (DC);
diabetic trained (DT). The exercise groups undertook a4 weeks resistance training program. All methods used
were approved by the Ethics Committee of the School of
Medical Sciences, Tarbiat Modares University.
Induction of diabetes
Diabetes was induced by a single intraperitoneal injection
of streptozotocin (STZ) at a dose of 55 mg/kg (Sigma-
Aldrich, St. Louis, MO). STZ was dissolved (20 mg/ml) in a
cold 0.1 M citrate buffer (pH 4.5). Non-diabetic rats were
injected with a similar volume of citrate buffer only. Five
days after the STZ injection, blood glucose concentration
was measured using tail vein blood samples obtained from
rats following overnight fasting. A blood glucose level >
14 mmol/L was considered indicative of diabetes.
Resistance training protocol
Resistance training was accomplished with the use of a 1-
m ladder inclined at 80°. There were 26 rungs evenly
spaced on the ladder. Before inducing diabetes, rats were
familiarized with the ladder by practicing climbing the lad-
der from the bottom to the top of ladder without any add-
itional weight. Rats were positioned at the bottom of
climbing apparatus and motivated to climb the ladder by
touching and grooming of the tail. When the rats reached
the top of the ladder, they were allowed to rest in a simu-
lated home. Resistance training was initiated 7 days after
injection of STZ using weights that were attached to the
base of tail with an adhesive tape and a clip. All animals
were weighed every 4 days to monitor weight gains and, for
the resistance trained animals, to determine the amount of
weight to append to their tails for the remainder of the
week. The training program was divided into two parts: the
preliminary phase of 2 weeks duration followed by a sus-
tained non-incremental resistance training intervention
phase of 2 weeks duration with the loading equivalent to
100% body mass (BM). In the preliminary phase, the rats
were adapted to climbing the ladder with progressive load-
ing on each successive training day. Both training groups of
rats performed 6 repetitions ascending the ladder inter-
spersed with 1:00 minute rest intervals. A second set was
performed after a 3:00 minutes rest. On the first day, rats
trained with the equivalent of 30% BM as load appended to
their tail (6 repetitions/2 sets). On the second day the train-
ing load was increased to 50% BM (6 reps/2 sets), and on
the third day an additional set of repetitions was under-
taken with 50% BM (6 reps/3 sets). Thereafter the training
load was gradually increased until the seventh day when
the training load reached 100% BM. In the final 2 weeks of
the resistance training phase, the rats continued to train
with 100% BM, 6 repetitions per set, 3 sets per day, and
3 days per week until the end of week 4. Each repetition
lasted ~ 4–6 s. The resistance training protocol was adapted
from Lee and Farrar [25] to meet the needs and focus of
the current research. Warming-up and cooling down
450
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weights appended to the tail, immediately pre and post
each training session. Non-trained (controls) rats were
handled on the same days and times as the trained
groups in order to minimize any stress attributable to
handling.
Euthanasia and sampling
To minimize any residual effect of the last training bout,
48 h after the last training session, rats were anesthe-
tized intraperitoneally with a mixture of Ketamine
(50 mg/kg) and Xylazine (3–5 mg/kg). Rats were sacri-
ficed between 9:00 and 12:00 a.m. after fasting overnight.
The abdominal cavity was opened following the median
line of the abdomen and approximately 6 ml of blood
was collected from the abdominal vena cava and was
collected in tubes containing EDTA. Blood was centri-
fuged (3000 rpm; 4°C; 15 min) and the plasma was kept
for further analyses.
Samples of liver was quickly collected from the ani-
mals and immediately frozen in liquid nitrogen. The
flexor hallucis longus (FHL) muscle (the major muscle
recruited in climbing activity), free from surrounding
tissues, was rapidly dissected from the right hind-limb,
weighed, and immediately frozen in liquid nitrogen.
The samples were placed into tubes with buffer con-
taining 0.9% NaCl, 50 mM Tris–HCl, 12 μM leupeptin.
They were then homogenized with a homogenizer
(Potter-Elvejheim) set at 800 rpm for 20 seconds.
After this procedure, the samples were centrifuged at
4.000 rpm for 10 minutes. The supernatant was ex-
tracted to determine the triglycerides and cholesterol.
























Figure 1 Body weights (g) of rats in non-diabetic control
(non-DC), non-diabetic trained (non-DT), diabetic control (DC),
and diabetic trained (DT) rats. * P < 0.05; significantly different
from Non-diabetic control. † P < 0.05; significantly different from
before 4 weeks.Biochemical measurements
Plasma glucose was determined by an enzymatic (GOD-
PAP, Glucose Oxidase-Amino Antipyrine) colorimetric
method (Pars Azmoun, Tehran, Iran). ELISA kits spe-
cific for rat studies were used to determine plasma insu-
lin (Mercodia AB, Uppsala, Sweden), apoA-I (Cusabio
Biothech, Wuhan, China), and FABP4 (Cusabio Biothech,
Wuhan, China) concentrations following the manufac-
turer’s instructions. Plasma high-density lipoprotein chol-
esterol (HDL-C) was determined by direct Colorimetric
Method (Randox, Antrim, UK), total Triglycerides (TG)
by enzymatic (Glycerol-3-Phosphate Oxidase) colorimetric
method (Pars Azmoun, Tehran, Iran), total Cholesterol
(TC) by enzymatic (Cholesterol Oxidase-Amino Antipy-
rine) colorimetric method (Pars Azmoun, Tehran, Iran),
and non-esterified fatty acids (NEFA) concentration by a
Colorimetric Method (Randox, Antrim, UK) following the
manufacturer’s instructions. The procedure of Friedewaldet al. was used to estimate low-density lipoprotein choles-
terol (LDL-C) according to the following formula:
LDL cholesterol ¼ total cholesterol−HDL cholesterol− Triglycerides=5ð Þ:
Statistical analysis
All statistical analyses were undertaken using the SPSS
program, version 16.0, for Windows. All values were
checked for normality using Kolmogorov-Smirnov test.
Paired sample Student’s t test was used to test the differ-
ence between pre and post of some parameters (for con-
tinuous variables). Comparisons between groups were
made using one-way analysis of variance (ANOVA) and
LSD’s test. Correlations analyses were performed using
Pearson’s method to examine the simple relationships
between plasma apoA-I and FABP4 concentration and
selected variables in diabetic and non-diabetic groups.
All data were expressed as mean ± SD and P value ≤0.05
was considered statistically significant.
Results
All of the trained animals successfully completed the
4 weeks of resistance training. The results of body weights
changes are shown in Figure 1. Initial body weights be-
tween the groups were not significantly different in this
study. Five days after the STZ injection (before 4 weeks of
resistance training), weight loss was shown in diabetic rats
(i.e., DC and DT). Final body weights of diabetic control























Figure 2 Plasma concentrations of apoA-I in non-diabetic
control (non-DC), non-diabetic trained (non-DT), diabetic
control (DC), and diabetic trained (DT) rats. The values are
presented as mean ± standard deviation of 8 animals per group.
*P < 0.05; significantly different from Non-diabetic control. † P < 0.05;
significantly different from Diabetic control.
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trol group significantly reduced after 4 weeks compared
with before the 4 weeks of training program (P = 0.019).
But in diabetic trained group we did not find any signifi-
cant difference between before and after 4 weeks of resist-
ance training program. The wet weight of the FHL muscle
in diabetic rats was significantly lower than in non-
diabetic groups (P < 0.05) (Table 1). The weight of the
FHL muscle was significantly greater in trained diabetic
rats compared with sedentary diabetic rats (P = 0.026).
Also, the ratio of FHL weight per whole body weight in
diabetic trained rats was significantly higher than in seden-
tary diabetic rats (P = 0.002).
Both diabetic (control and trained) groups had signifi-
cantly higher plasma glucose and lower insulin concen-
trations than non-diabetic (control and trained) groups
(Table 1). Four weeks’ resistance training did not signifi-
cantly affect the plasma glucose and insulin concentra-
tions in diabetic and non-diabetic groups. Plasma levels
of total cholesterol, triglycerides, NEFA, and LDL-C did
not differ between all groups. After 4 weeks resistance
training plasma HDL-C level in diabetic trained group
was higher compared with diabetic control group (P =
0.048). The statistical analysis did not show a significant
difference in liver cholesterol concentrations between all
groups. Liver triglycerides concentrations were signifi-
cantly lower in non-diabetic trained and diabetic trained
groups compared with their control groups (respectively,
P = 0.041 and P = 0.002).
Diabetic inducing increased plasma apoA-I (P = 0.001)
levels compared with non-diabetic control rats (Figure 2).
After 4 weeks’ resistance training, plasma levels of apoA-I
in the diabetic trained rats was significantly higher com-
pared with the diabetic control group (P = 0.003).
Plasma level of FABP4 was significantly (P = 0.041)
lower in control diabetic rats compared with non-diabeticTable 1 Plasma Concentrations of glucose, insulin, lipid profil
Non-diabetic control Non
Glucose (mg/dl) 126 ± 5.8 130
Insulin (μg/L) 0.43 ± 0.11 0.45
Total cholesterol (mg/dl) 75.4 ± 9.7 79.6
Triglycerides (mg/dl) 64.6 ± 10.9 60.4
HDL- cholesterol (mg/dl) 27.4 ± 1.5 27.6
LDL- cholesterol (mg/dl) 36.4 ± 7.9 39.9
Non-esterified fatty acid (mM) 0.78 ± 0.14 0.83
Liver cholesterol (mg/g) 4.1 ± 2.31 2.8 ±
Liver triglycerides (mg/g) 34.6 ± 4.5 28.3
FHL (mg) 508.2 ± 35.2 478.
FHL/body weight (mg/g) 1.40 ± 0.09 1.40
The values are presented as mean ± standard deviation of eight animals per group
significantly different from Diabetic control.control group (Figure 3). Four weeks’ resistance training
significantly increased plasma FABP4 levels compared
with diabetic control group (P = 0.017).
We examined the correlation between plasma apoA-I
and FABP4 concentrations and body weights and FHL
muscle mass in both diabetic and non-diabetic rats
(Table 2). In diabetic rats plasma apoA-I and FABP4
concentrations correlated positively with FHL muscle
mass and ratio of FHL per body weight. However in
non-diabetic group plasma apoA-I and FABP4 concen-
trations were not significantly correlated with these pa-
rameters. Plasma FABP4 levels in diabetic rats positivelye, and liver cholesterol and triglycerides
-diabetic trained Diabetic control Diabetic trained
± 6.5 338 ± 29.9* 346 ± 15.6*
± 0.07 0.17 ± 0.07* 0.16 ± 0.06*
± 10.9 73.9 ± 11.5 80.7 ± 7.8
± 7.2 69.0 ± 14.6 70.7 ± 7.0
± 3.3 26.3 ± 4.1 30.4 ± 5.5†
± 10.1 33.8 ± 11.1 36.2 ± 6.1
± 0.17 0.77 ± 0.13 0.82 ± 0.14
1.07 5.0 ± 1.66 3.8 ± 1.62
± 5.7* 31.4 ± 7.4 21.4 ± 4.6*†
5 ± 61.7 286.2 ± 46.1* 334.0 ± 37.6†
± 0.10 1.13 ± 0.11* 1.28 ± 0.10†



























Figure 3 Plasma concentrations of FABP4 in non-diabetic
control (non-DC), non-diabetic trained (non-DT), diabetic
control (DC), and diabetic trained (DT) rats. The values are
presented as mean ± standard deviation of 8 animals per group.
*P < 0.05; significantly different from Non-diabetic control. † P < 0.05;
significantly different from Diabetic control.
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significant (r = 0.496, P = 0.051).
Discussion
In this experimental study, we found that hyperglycemia
in streptozotocin- induced diabetic rats was associated
with higher plasma apoA-I and lower FABP4 levels than
non-diabetic control rats. Also, 4 weeks’ resistance train-
ing increased plasma FABP4 and apoA-I levels in diabetic
trained rats when compared with diabetic control group.
ApoA-I, the major protein of HDL, is produced in both
the liver and the intestine and is secreted into the plasma
as a lipid-poor apolipoprotein. ApoA-I production would
stimulate physiological formation of new HDL particles,
which would carry out their biological activity and is sup-
ported by observations from animal models that transgenic
expression of apoA-I is atheroprotective [26].Table 2 Pearson correlation between plasma apoA-I and FABP
both diabetic and non-diabetic rats
apoA-I
Diabetic (n = 16) Non- diabet
r (P value) r (P va
Final body weight (g) 0.396 (0.129) - 0.099 (
Weight gain (g) 0.455 (0.077) - 0.485 (
FHL (mg) 0.577 (0.019) 0.056 (0
FHL/body weight (mg/g) 0.544 (0.029) 0.274 (0
Weight gain = Final body weight- Initial body weight.In the present study, we found that plasma levels of
apoA-I in diabetic control group was higher compared
with the non-diabetic control group. In accordance with
this finding many studies have demonstrated that, in the
absence of renal failure, HDL-C and apoA-I are often
higher in subjects with type 1 diabetes than in the control
population [27,28]. It has been indicated that patients with
type 1 diabetes have greatly increased phospholipid trans-
fer protein (PLTP) activity [29], and higher PLTP activity
was associated with more circulating apoA-I levels [28].
Thus, it seems that higher PLTP activity makes an import-
ant contribution to the higher apoA-I levels and altered
HDL subclass distribution in type 1 diabetes [28].
Few studies have investigated the effects of exercise
training on circulating apoA-I levels in subjects with type
1 diabetes mellitus. Lehmann et al. [30] reported that
3 month increased of physical activity from 195 ± 176 to
356 ± 164 min associated with enhanced plasma apoA-I
levels in subjects with type 1 diabetes mellitus [30]. Also,
increased of circulating apoA-I and HDL levels was found
in young men with type 1 diabetes mellitus after 12–
16 week endurance exercise program [31]. To our know-
ledge, in the present study, for the first time we shown
that 4 weeks of resistance training was associated with
higher plasma apoA-I and HDL levels in type 1 diabetic
rats compared with control group. The underlying mecha-
nisms responsible for alterations in circulating apoA-I
levels due to exercise training is poorly understood. It is
indicated that adiponectin enhanced apoA-I synthesis in
the liver [32]. Although in this study we did not assessed
plasma adiponectin concentrations, increased of circulat-
ing adiponectin levels reported in several studies due to
exercise training [33,34]. Also, increase of ABCA1 expres-
sion, and ApoA-I and some other factors involved in the
process of cholesterol reverse transport such as lecithin
cholesteryl acyl transferase (LCAT), cholesteryl ester
transfer protein (CETP), PLTP and Scavenger receptor BI
(SR-BI) have been suggested the main mechanisms of in-
creasing HDL-C [35].
While several studies have examined the effects of
FABP4 expression on adiposity, insulin resistance, meta-
bolic syndrome, and type 2 diabetes, there are only limited4 levels and muscle and body weights parameters in
FABP4
ic (n = 16) Diabetic (n = 16) Non- diabetic (n = 16)
lue) r (P value) r (P value)
0.717) 0.496 (0.051) - 0.109 (0.689)
0.057) 0.461 (0.072) - 0.023 (0.933)
.836) 0.683 (0.004) 0.143 (0.597)
.305) 0.647 (0.007) 0.437 (0.090)
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studies indicated that circulating FABP4 levels are consid-
ered to be a link between obesity, insulin resistance, dia-
betes, and cardiovascular diseases [10]. Moreover, some
of studies shown that circulating FABP4 levels were in-
creased in overweight and obese subjects compared with
lean controls, and was associated with markers of insulin
resistance and obesity [10]. While weight reduction associ-
ated with decline of circulating FABP4 levels [36]. In ac-
cordance with these studies, we found that lower plasma
FABP4 levels in STZ-induced diabetic rats accompanied
with significant weight reduction.
Although high levels of circulating FABP4 has been
suggested as a biomarker of metabolic syndrome [9],
controversial results found in chronic pancreatitis [17],
and lean type 1 diabetic patients [18]. Also, Hsu et al.
[37] did not find any significant differences in serum
FABP4 levels between type 1 and type 2 diabetic patients
[37]. In the present study, decreased of plasma FABP4
level was associated with hyperglycemia induced by STZ
injection. It seems that alterations in body weights to be
an effective factor in contradictory observations in previ-
ous studies. Significant differences in circulating FABP4
concentrations were found in studies that significant dif-
ferences in body weights between groups has been
found. On the other hand, high levels of blood glucose
and inflammatory markers were not always associated
with increased circulating FABP4 levels [37,38]. Also,
plasma FABP4 in obese type 1 diabetic patients were sig-
nificantly higher than in non-obese type 1 diabetic pa-
tients [18]. Thus, it seems that adipocyte hypertrophy
induced by weight gain and adiposity result in elevation
of FABP4 expressions and subsequent release into the
bloodstream. In this regard, Skurk et al. suggested that
adipocyte size is an important determinant of adipokine
secretion [39]. However, further studies are needed in
order to determine the main factors affecting circulating
FABP4 levels.
Few studies have investigated the effects of exercise
training on circulating FABP4 levels. After 3 months of
the exercise training in obese women, serum FABP4
levels decreased significantly along with a reduction in
body weight, BMI, waist circumference, fasting glucose
and total cholesterol levels [40]. Also, Lázaro et al. [41]
indicated that increasing aerobic physical activity can de-
crease plasma FABP4 levels, independently of weight re-
duction in patients with cardiovascular risk [41]. While,
FABP4 gene expression was significantly elevated after
10 weeks of aerobic training in the epididymal and retro-
peritoneal adipose tissues of Obese Zucker rats. More-
over, Fischer et al. [42] found that FABP4 mRNA and
protein expressions were much higher in endurance
trained compared to control individuals [42]. In the
present study trained diabetic rats have a higher plasmaFABP4 levels than diabetic control group. Moreover, this
exercise training program leads to preventing of weight re-
duction induced by diabetic induction. Thus, it seems this
training program with inhibiting weight reduction have a
regulatory function for circulating FABP4 levels. Interest-
ingly, we found positive correlation between plasma FABP4
levels and muscle and body weight in diabetic rats. On the
other hand, previous studies indicated that exercise training
result in significant increase in muscle FABP4 levels [38].
Thus, in the present study higher plasma FABP4 levels in
trained rats could be partly due to the influence of resist-
ance training on muscle FABP4 contents and releasing in
bloodstream.
We did not find any significant changes in plasma lipid
profile and liver cholesterol levels after 4 week resistance
training despite enhanced plasma FABP4 levels. However,
liver triglyceride levels in trained groups were significantly
lower than control groups. In accordance with this find-
ing, previous studies indicated that resistance training
could reduce liver fat content [43]. For example, signifi-
cant reduction of liver fat was observed in patients with
non-alcoholic fatty liver after 8 week resistance training a
long with improve in glucose metabolism [44]. Moreover
similar results found in studies with animal models. In
ovariectomized or normal rats 12 weeks resistance train-
ing decreased muscle and liver lipid contents [22,45]. Also,
improved serum lipid profile was observed in rats fed with
normal or high-fat diets after 8 weeks of resistance train-
ing [24]. Thus, it seems that relatively short duration of re-
sistance training program used in this study compared
with previous studies, and low energy consumption in-
duced by this type of training compared with aerobic
training could be reasons for no significant changes in cir-
culating lipid profile.Conclusions
These results indicate that resistance training increases
serum apoA-I and FABP4 concentrations in streptozotocin-
induced diabetic rats. Inhibiting role of resistance training in
weight loss induced by diabetic induction may be one of ef-
fective mechanisms for this observation. However, further
research is needed to elucidate physiological significance of
circulating FABP4 levels.
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